Cargando…

Low‐grade BRAF V600E mutant oligodendroglioma‐like tumors of children may show EGFR and MET amplification

Detalles Bibliográficos
Autores principales:	Yang, Rui Ryan, Li, Kay Ka‐Wai, Liu, Anthony P.Y., Chen, Hong, Chung, Nellie Yuk‐Fei, Chan, Aden K.Y., Li, Fangcheng, Chan, Danny Tat‐Ming, Mao, Ying, Shi, Zhi‐Feng, Ng, Ho‐Keung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018073/ https://www.ncbi.nlm.nih.gov/pubmed/33032379 http://dx.doi.org/10.1111/bpa.12904

Ejemplares similares

MPC-14 BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENTS AND YOUNG ADULTS
por: Fukuoka, Kohei, et al.
Publicado: (2019)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Biomarker-based prognostic stratification of young adult glioblastoma
por: Zhang, Rui-qi, et al.
Publicado: (2015)

Combination genetic signature stratifies lower-grade gliomas better than histological grade
por: Chan, Aden Ka-Yin, et al.
Publicado: (2015)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
por: Li, Yan-Xi, et al.
Publicado: (2016)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Regression of BRAF(V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases
por: Woo, Peter Y.M., et al.
Publicado: (2019)

EGFR blockade prevents glioma escape from BRAF(V600E) targeted therapy
por: Yao, Tsun-Wen, et al.
Publicado: (2015)

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF(V600E) mutation: a case report and review of literature
por: Zeng, Ran, et al.
Publicado: (2021)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication
por: Chan, Aden Ka-Yin, et al.
Publicado: (2022)

Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR
por: Huang, Tiangui, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation
por: Byeon, Hyung Kwon, et al.
Publicado: (2016)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Complete response with fluorouracil and irinotecan with a BRAF(V600E) and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report
por: Wang, Zhan, et al.
Publicado: (2019)

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors
por: Ruiz-Saenz, Ana, et al.
Publicado: (2023)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Design and synthesis of new thiazolidinone/uracil derivatives as antiproliferative agents targeting EGFR and/or BRAF(V600E)
por: Alshammari, Mohammed B., et al.
Publicado: (2022)

Molecular landscapes of longitudinal NF2 /22q and non‐NF2 /22q meningiomas show different life histories
por: Ng, Ho‐Keung, et al.
Publicado: (2022)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Oligodendroglioma in childhood.
por: Wang, K. C., et al.
Publicado: (1993)

Imaging of oligodendroglioma
por: Smits, Marion
Publicado: (2016)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

Oligodendroglioma arising in a sacrococcygeal immature teratoma.
por: Jung, Chan Kwon, et al.
Publicado: (2002)

SMAD4 is Critical in Suppression of BRAF-V600E Serrated Tumorigenesis
por: Tong, Kevin, et al.
Publicado: (2021)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2021)

Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAF(V600E)
por: El-Kalyoubi, Samar A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ir4vs0tg9gpq6cn4k6r5lplgus